INCYTE - Dusseldorf Stock Exchang (ICY DU) stock market data APIs
€84.6641
1.66(2%)
as of December 8, 2025
Try our APIs with
free plan!
INCYTE - Dusseldorf Stock Exchang Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for ICY.DU.
Prev. Close
84.6641
Open
86.3248
High
88.6282
Low
82.5668
52 wk Range
48.52-93.58
Market Cap
12 792 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get INCYTE - Dusseldorf Stock Exchang data using free add-ons & libraries
Get INCYTE - Dusseldorf Stock Exchang Fundamental Data
INCYTE - Dusseldorf Stock Exchang Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
INCYTE - Dusseldorf Stock Exchang News
New
Incyte Stock Falls Despite FDA Breakthrough Therapy Fast Track For Rare Blood Cancer Drug
Incyte Stock Falls Despite FDA Breakthrough Therapy Fast Track For Rare Blood Cancer Drug The FDA granted Breakthrough Therapy status to Incyte's experimental treatment for a rare blood cancer. Incyte stock fell from near five-year highs. Continue Reading
Incyte Gets FDA Breakthrough Therapy Fast Track For Rare Blood Cancer Drug
Incyte Gets FDA Breakthrough Therapy Fast Track For Rare Blood Cancer Drug The FDA granted Breakthrough Therapy status to Incyte's experimental treatment for a rare blood cancer. Incyte stock is basing near five-year highs. Continue Reading
Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025
Rapid and robust reductions in spleen volume and symptoms, and improvements in anemia were observed with INCA033989 as monotherapy and in combination with ruxolitinib (Jakafi®) in patients with myelo...
Incyte’s First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA
The Company plans to initiate a Phase 3 program evaluating INCA033989 in essential thrombocythemia (ET) patients with all types of CALR mutations in mid-2026, following alignment with regulators Updat...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
